Privium Fund Management B.V. Acquires New Stake in Sarepta Therapeutics, Inc. $SRPT

Privium Fund Management B.V. bought a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor bought 39,400 shares of the biotechnology company’s stock, valued at approximately $698,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Center for Financial Planning Inc. acquired a new position in shares of Sarepta Therapeutics during the 1st quarter valued at $31,000. Ancora Advisors LLC raised its position in Sarepta Therapeutics by 150.0% in the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 300 shares in the last quarter. Banque Transatlantique SA bought a new stake in Sarepta Therapeutics in the first quarter worth about $44,000. Pandora Wealth Inc. acquired a new stake in Sarepta Therapeutics in the 1st quarter valued at about $45,000. Finally, Brooklyn Investment Group boosted its position in shares of Sarepta Therapeutics by 450.4% during the 1st quarter. Brooklyn Investment Group now owns 721 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 590 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Price Performance

SRPT opened at $23.05 on Tuesday. The firm has a market capitalization of $2.25 billion, a P/E ratio of -26.49 and a beta of 0.51. The stock has a fifty day moving average of $19.72 and a 200-day moving average of $28.79. The company has a quick ratio of 1.81, a current ratio of 2.89 and a debt-to-equity ratio of 0.84. Sarepta Therapeutics, Inc. has a 12-month low of $10.41 and a 12-month high of $138.81.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $0.89 by $1.13. The business had revenue of $611.09 million for the quarter, compared to the consensus estimate of $530.66 million. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.Sarepta Therapeutics’s revenue for the quarter was up 68.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.07 earnings per share. Equities analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on SRPT. Needham & Company LLC reiterated an “underperform” rating on shares of Sarepta Therapeutics in a report on Monday, July 28th. William Blair reaffirmed an “outperform” rating on shares of Sarepta Therapeutics in a report on Tuesday, July 29th. UBS Group reiterated a “neutral” rating on shares of Sarepta Therapeutics in a research report on Monday, July 21st. Jefferies Financial Group decreased their target price on Sarepta Therapeutics from $40.00 to $35.00 and set a “buy” rating on the stock in a report on Thursday, July 24th. Finally, Leerink Partners boosted their target price on Sarepta Therapeutics from $12.00 to $15.00 and gave the stock a “market perform” rating in a research report on Tuesday, September 9th. Eight analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and seven have given a Sell rating to the company. Based on data from MarketBeat, Sarepta Therapeutics currently has an average rating of “Hold” and a consensus price target of $34.42.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.